2.16
0.00 (0.00%)
| Penutupan Terdahulu | 2.16 |
| Buka | 2.15 |
| Jumlah Dagangan | 1,611,420 |
| Purata Dagangan (3B) | 2,775,659 |
| Modal Pasaran | 694,120,320 |
| Harga / Buku (P/B) | 4.24 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 Aug 2025 - 1 Sep 2025 |
| Margin Operasi (TTM) | -635.44% |
| EPS Cair (TTM) | -0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -13.50% |
| Nisbah Semasa (MRQ) | 14.55 |
| Aliran Tunai Operasi (OCF TTM) | -46.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -32.27 M |
| Pulangan Atas Aset (ROA TTM) | -36.11% |
| Pulangan Atas Ekuiti (ROE TTM) | -53.99% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | CLARITY PH FPO [CU6] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.38 |
|
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 27.52% |
| % Dimiliki oleh Institusi | 13.79% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |